American pharmaceutical giant Eli Lilly, a competitor to Danish Novo Nordisk on the market for weight loss preparations, rises 2.6 percent in pre-trading on the New York Stock Exchange, following today's financial report.
The company's financial report was in line with the preliminary results that Eli Lilly announced to the market already a month ago, with revenues amounting to 13.5 billion dollars and earnings per share written at 5.32 dollars. Over the past two years, demand for the company's weight loss preparations Zepbound and Mounjaro has surged strongly, and the company has therefore also made billion-dollar investments to meet demand.
Regarding Mounjaro specifically, the company reports a 60-percent increase in revenues for the fourth quarter compared to the same period in 2024.
